Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Loss of corticospinal tract integrity in early MS disease stages.
Pawlitzki M, Neumann J, Kaufmann J, Heidel J, Stadler E, Sweeney-Reed C, Sailer M, Schreiber S. Pawlitzki M, et al. Neurol Neuroimmunol Neuroinflamm. 2017 Sep 25;4(6):e399. doi: 10.1212/NXI.0000000000000399. eCollection 2017 Nov. Neurol Neuroimmunol Neuroinflamm. 2017. PMID: 28959706 Free PMC article.
MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.
Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B. Jarius S, et al. Among authors: pawlitzki m. J Neuroinflammation. 2018 Mar 19;15(1):88. doi: 10.1186/s12974-018-1108-6. J Neuroinflammation. 2018. PMID: 29554927 Free PMC article. Review.
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, Kleinschnitz C, Kleinschnitz K, Rogall R, Pape K, Bittner S, Zipp F, Warnke C, Goereci Y, Schroeter M, Ingwersen J, Aktas O, Klotz L, Ruck T, Wiendl H, Meuth SG. Rolfes L, et al. Among authors: pawlitzki m. Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5):e1035. doi: 10.1212/NXI.0000000000001035. Print 2021 Sep. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34261812 Free PMC article.
Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.
Stork L, Brück W, von Gottberg P, Pulkowski U, Kirsten F, Glatzel M, Rauer S, Scheibe F, Radbruch H, Hammer E, Stürner KH, Kaulen B, Heesen C, Hoffmann F, Brock S, Pawlitzki M, Bopp T, Metz I. Stork L, et al. Among authors: pawlitzki m. Mult Scler. 2019 Oct;25(12):1618-1632. doi: 10.1177/1352458518819098. Epub 2019 Jan 18. Mult Scler. 2019. PMID: 30657420
High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
Schneider-Hohendorf T, Schulte-Mecklenbeck A, Ostkamp P, Janoschka C, Pawlitzki M, Luessi F, Zipp F, Meuth SG, Klotz L, Wiendl H, Gross CC, Schwab N. Schneider-Hohendorf T, et al. Among authors: pawlitzki m. Mult Scler. 2021 Sep;27(10):1491-1496. doi: 10.1177/1352458520970103. Epub 2020 Nov 5. Mult Scler. 2021. PMID: 33150829 Free PMC article.
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
Pfeuffer S, Ruck T, Pul R, Rolfes L, Korsukewitz C, Pawlitzki M, Wildemann B, Klotz L, Kleinschnitz C, Scalfari A, Wiendl H, Meuth SG. Pfeuffer S, et al. Among authors: pawlitzki m. J Neurol Neurosurg Psychiatry. 2021 Sep;92(9):1007-1013. doi: 10.1136/jnnp-2020-325304. Epub 2021 Mar 12. J Neurol Neurosurg Psychiatry. 2021. PMID: 33712515 Free PMC article.
87 results